← Leaderboards
Vinata B Lokeshwar
University Of Miami School Of Medicine
$10,655,590
Attributed
$11,278,090
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,278,090 · 10
By mechanism
R01$10,686,641 · 7
R21$367,249 · 1
R29$214,200 · 1
R13$10,000 · 1
Top collaborators
- Balakrishna L. Lokeshwar2 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Keith Brew$5,215,859
- Balakrishna L. Lokeshwar$5,068,178
Others in their field
Top investigators on “Tissues”
- David Heimbrook · Leidos Biomedical Research, Inc.$346,311,904
- Lawrence Corey · Fred Hutchinson Cancer Center$230,011,824
- Larry Arthur$159,140,370
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Judith S. Currier · University Of California Los Angeles$138,805,403
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$138,805,403
Research focus
TissuesNeoplasm MetastasisTumorSpecimenGrowthMediatingResistanceToxic EffectResponseEnzymesMolecularIn VitroSignal TransductionFda ApprovedTumor GrowthGlycosaminoglycansDesignFamilyBaseNeoplastic CellHyaluronic AcidEvaluationImmunohistochemistryMalignant Neoplasms
Grant awards (40)
Glycosaminoglycan Targeting Treatment for Prostatic Hyperplasia and Fibrosis$615,750
R01 · FY2025 · DK · contact PI
Biomarker guided combinations for treating high-risk bladder cancer$557,016
R01 · FY2025 · CA · contact PI
Glycosaminoglycan Targeting Treatment for Prostatic Hyperplasia and Fibrosis$629,250
R01 · FY2024 · DK · contact PI
Biomarker guided combinations for treating high-risk bladder cancer$529,168
R01 · FY2024 · CA · contact PI
Biomarker guided combinations for treating high-risk bladder cancer$557,016
R01 · FY2023 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$429,841
R01 · FY2023 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$445,248
R01 · FY2022 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$15,721
R01 · FY2021 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$454,334
R01 · FY2020 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$436,411
R01 · FY2019 · CA · contact PI
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma$324,708
R01 · FY2019 · CA · contact PI
Novel Biomarkers for the Clinical Management of Bladder Cancer$466,211
R01 · FY2018 · CA · contact PI
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma$341,059
R01 · FY2018 · CA · contact PI
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma$315,592
R01 · FY2016 · CA · contact PI
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma$346,483
R01 · FY2015 · CA · contact PI
Role of CYP3A4 in Prostate Cancer$179,945
R21 · FY2015 · CA · contact PI
Role of CYP3A4 in Prostate Cancer$20,373
R21 · FY2015 · CA · contact PI
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma$329,001
R01 · FY2014 · CA · contact PI
Mechanisms of Bladder Cancer Progression$177,741
R01 · FY2014 · CA · contact PI
Role of CYP3A4 in Prostate Cancer$166,931
R21 · FY2014 · CA · contact PI
Mechanisms of Bladder Cancer Progression$66,367
R01 · FY2014 · CA · contact PI
Mechanisms of Bladder Cancer Progression$1
R01 · FY2013 · CA · contact PI
Mechanisms of Bladder Cancer Progression$264,728
R01 · FY2012 · CA · contact PI
Mechanisms of Bladder Cancer Progression$264,728
R01 · FY2011 · CA · contact PI
Mechanisms of Bladder Cancer Progression$272,865
R01 · FY2010 · CA · contact PI
Glycosaminoglycan-based inhibitors for treatment of prostate cancer$260,623
R01 · FY2010 · CA · contact PI
Mechanisms of Bladder Cancer Progression$266,619
R01 · FY2009 · CA · contact PI
Glycosaminoglycan-based inhibitors for treatment of prostate cancer$260,623
R01 · FY2009 · CA · contact PI
19th Annual SBUR Meeting: Molecular Targets for Diagnostic and Therapeutics in Ur$10,000
R13 · FY2009 · DK · contact PI
Glycosaminoglycan-based inhibitors for treatment of prostate cancer$260,623
R01 · FY2008 · CA · contact PI
Glycosaminoglycan-based inhibitors for treatment of prostate cancer$260,482
R01 · FY2007 · CA · contact PI
Mechanisms of Bladder Cancer Progression$262,214
R01 · FY2006 · CA · contact PI
Mechanisms of Bladder Cancer Progression$268,524
R01 · FY2005 · CA
Glycosaminoglycans For IC Pathophysiology and Prognosis$150,764
R01 · FY2005 · DK
Mechanisms of Bladder Cancer Progression$268,524
R01 · FY2004 · CA
Glycosaminoglycans For IC Pathophysiology and Prognosis$150,764
R01 · FY2004 · DK
Mechanisms of Bladder Cancer Progression$286,878
R01 · FY2003 · CA
Glycosaminoglycans For IC Pathophysiology and Prognosis$150,764
R01 · FY2003 · DK
MECHANISIMS OF BLADDER CANCER PROGRESSION$107,100
R29 · FY2001 · CA
MECHANISIMS OF BLADDER CANCER PROGRESSION$107,100
R29 · FY2000 · CA